Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data
Efficacy Data On Casirivimab/Imdevimab In Mutant Strains Forthcoming
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
You may also be interested in...
The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
The bamlanivimab/etesevimab combo, filed for US emergency authorization in November, shows ability to reduce risk of hospitalization or death in COVID-19 patients. Lilly also sees prevention role for bamlanivimab.